Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Lowered to $202 at BMO Capital

November 10, 2021 6:33 AM
BMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $202.00 (from $205.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles